GLP1R and type 2 diabetes mellitus: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose co-transporter-2 inhibitors (SGLT-2is) are established therapies for type 2 diabetes (T2D) (1).